We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals
AMPH

104 hedge funds and large institutions have $261M invested in Amphastar Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 47 increasing their positions, 25 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 8

88% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 25

52% more capital invested

Capital invested by funds: $172M → $261M (+$89.3M)

9% more funds holding

Funds holding: 95 → 104 (+9)

Holders
104
Holders Change
+9
Holders Change %
+9.47%
% of All Funds
2.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
47
Reduced
25
Closed
8
Calls
$691K
Puts
–
Net Calls
+$691K
Net Calls Change
+$691K

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$5.17M
2
BIT
BlackRock Institutional Trust
California
+$3.63M
3
EI
EAM Investors
California
+$3.48M
4
KI
Kalmar Investments
Delaware
+$2.97M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.86M

Top Sellers

Rank Fund Capital Flow
1
SGAM
Smith Group Asset Management
Texas
-$1.45M
2
ECM
Endurant Capital Management
California
-$1.29M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.26M
4
UBS AM
UBS AM
Illinois
-$1.01M
5
State Street
State Street
Massachusetts
-$632K

AMPH Hedge Fund Activity: Q2 2016 in Review

104 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2016, worth a combined $261M — up 52% from $172M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new AMPH positions and 8 closed out — a net gain of 11 holders — while 47 added to existing stakes and 25 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $5.17M. The largest seller was Smith Group Asset Management, cutting an estimated $1.45M.

  • 104 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2016, up from 95 in Q1 2016.
  • Funds reported $261M of Amphastar Pharmaceuticals stock for Q2 2016, up 52% quarter-over-quarter.
  • 19 funds opened new Amphastar Pharmaceuticals positions in Q2 2016 and 8 closed out, a net change of +11 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q2 2016 was Acadian Asset Management, an estimated $5.17M added.
  • The largest Amphastar Pharmaceuticals seller in Q2 2016 was Smith Group Asset Management, an estimated $1.45M sold.

Based on aggregated 13F filings for Q2 2016.